This announcement is a separate document:
四川百利天恒药业股份有限公司自愿披露关于BL-B01D1（EGFR×HER3-ADC）用于EGFR-TKI治疗失败的EGFR敏感突变局部晚期或转移性非小细胞肺癌III期临床试验完成首例受试者入组的公告
Sichuan Baili Tianheng Pharmaceutical Co., Ltd. voluntarily disclosed an announcement on the completion of the BL-B01D1 (EGFR×HER3-ADC) phase III clinical trial for EGFR-sensitive mutant locally advanced or metastatic non-small cell lung cancer that failed EGFR-TKI treatment
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.